UP Oncolytics
Company Details
Status: Private
Employees: 1-10
Location:
North Chicago, Illinois, United States
Type:
sample
Technology:
sample
About: Founded in 2022, UP Oncolytics is engaged in the development of viral vectors to treat refractory and poorly responsive cancers like glioblastoma (GBM) and metastatic melanoma.
Despite intensive research efforts, many cancers do not respond to precision therapeutics because of challenges in drug delivery, heterogeneity of the tumor, and an immuno-inhibitory tumor microenvironment. Oncolytic viruses overcome all these challenges.
Our initial focus is on GBM, an aggressive brain cancer. Brain cancer is the leading cause of cancer deaths for people under 40 years of age in the United Kingdom, for men under 40 and women under 20 in the United States. In over a century, the overall survival for GBM patients has not significantly changed. The Central Brain Tumor Registry in the United States (CBTRUS) reported that the median survival for adults with GBM is 8 months with 6.8% of patients surviving to 5 years. At UP Oncolytics, we understand new approaches are desperately needed and we are actively working on solutions.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
UP Oncolytics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.